FULC
FULCRUM THERAPEUTICS, INC.Marquee-fund ownership over time
This quarter's activity
New positions opened
Positions exited
None.
Current holders
Sorted by tenure (longest first)| Fund | First disclosed | Held | Entry price | Latest close | Return on entry |
|---|---|---|---|---|---|
| Renaissance Technologies re-entered | Q3 2024(8Q snapshot) | 7Q | $8.86 | $6.09 | -31% |
| Citadel Advisors | Q3 2024(8Q snapshot) | 7Q | $9.02 | $6.09 | -32% |
| Two Sigma Investments re-entered | Q3 2024(8Q snapshot) | 7Q | $9.02 | $6.09 | -32% |
| D.E. Shaw | Q3 2024(8Q snapshot) | 7Q | $9.02 | $6.09 | -32% |
| Millennium Management | Q3 2024(8Q snapshot) | 7Q | $9.02 | $6.09 | -32% |
| AQR Capital Management re-entered | Q4 2024(8Q snapshot) | 6Q | $3.32 | $6.09 | +83% |
| Point72 Asset Management re-entered | Q3 2025(8Q snapshot) | 3Q | $6.60 | $6.09 | -8% |
“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.
Insider activity
Form 4 — officers, directors, 10%+ ownersFiled within two business days of each transaction by anyone with material insider status at Fulcrum Therapeutics, Inc.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.
30d / 90d windows measured from May 1, 2026 — the most recent Form 4 on file — not from today.
- Form 40001193125-26-201468May 1, 2026
- Form 4/Aamend0001193125-26-037606Feb 4, 2026
- Form 40001193125-26-037576Feb 4, 2026
- Form 40001193125-26-037574Feb 4, 2026
- Form 40001193125-26-037573Feb 4, 2026
- Form 40001193125-26-037575Feb 4, 2026
- Form 40001193125-26-037572Feb 4, 2026
- Form 40001193125-26-004572Jan 6, 2026
- Form 40001193125-25-322740Dec 17, 2025
- Form 40001231919-25-000596Dec 10, 2025
- Form 40001193125-25-291392Nov 21, 2025
- Form 40000950170-25-091584Jun 30, 2025
- Form 40000950170-25-091583Jun 30, 2025
- Form 40000950170-25-091582Jun 30, 2025
- Form 40000950170-25-091585Jun 30, 2025
Fundamentals
XBRL · FULCRUM THERAPEUTICS, INC.Annual figures sourced directly from FULCRUM THERAPEUTICS, INC.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for Fulcrum Therapeutics, Inc. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- 8-KMaterial eventJun 4, 2026
- 8-KMaterial eventJun 1, 2026
- DEF 14AProxy statementApr 30, 2026
- 10-QQuarterly reportApr 27, 2026
- 8-KMaterial eventApr 27, 2026
- 10-KAnnual reportFeb 24, 2026
- 8-KMaterial eventFeb 24, 2026
- 8-KMaterial eventJan 12, 2026
- 8-KMaterial eventDec 11, 2025
- 8-KMaterial eventDec 8, 2025
- 10-QQuarterly reportOct 29, 2025
- 8-KMaterial eventOct 29, 2025
- 8-KMaterial eventAug 28, 2025
- 10-QQuarterly reportJul 29, 2025
- 8-KMaterial eventJul 29, 2025
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| Two Sigma Investments | Q2 2026 | open | $6.69 | $6.09 | -9% |
| AQR Capital Management | Q1 2026 | open | $11 | $6.09 | -43% |
| Point72 Asset Management | Q1 2026 | open | $11 | $6.09 | -43% |
| Point72 Asset Management | Q3 2025 | Q4 2025 | $6.60 | $8.65 | +31% |
| Renaissance Technologies | Q2 2025 | open | $5.63 | $6.09 | +8% |
| AQR Capital Management | Q4 2024 | Q4 2025 | $3.32 | $8.65 | +161% |
| Citadel Advisors | Q3 2024 | open | $9.02 | $6.09 | -32% |
| Two Sigma Investments | Q3 2024 | Q4 2025 | $9.02 | $8.65 | -4% |
| D.E. Shaw | Q3 2024 | open | $9.02 | $6.09 | -32% |
| Millennium Management | Q3 2024 | open | $9.02 | $6.09 | -32% |
| Renaissance Technologies | Q3 2024 | Q4 2024 | $8.86 | $3.56 | -60% |
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.